Pseudocapacitance enhanced by N-defects in Na3MnTi(PO4)3/N-doped carbon composite for symmetric full sodium-ion batteries

Abstract

The concept of symmetric full battery attracts increasing attention in recent years. The symmetric battery consists of two identical ‘bifunctional’ electrode materials, which can be used as both the cathode and anode. The NASICON-structured Na3MnTi(PO4)3 is capable to be used as a bifunctional electrode for symmetric sodium-ion full battery because of its multiredox reaction with a suitable voltage gap. However, it suffers from limited capacity and poor rate performance. In this study, Na3MnTi(PO4)3 particulates embedding in the N-doped carbon matrix material (NMTP/C–N) are constructed. Both the experiments and density functional theory (DFT) calculations show that the N-defects in the carbon matrix have stronger adsorption energy toward Na+, and the N-vacancy defects have lower diffusion barriers for sodium-ion diffusion, thus enabling higher pseudocapacitance of the NMTP/C–N. By virtue of the enhanced reaction kinetics and pseudocapacitance, the NMTP/C–N demonstrates improved specific capacity and high-rate capability in both high- and low-voltage ranges (2.5–4.2 V vs. Na/Na+; 1.5–2.5 V vs. Na/Na+), where it is operated as the cathode and anode basing on the redox of Mn2+/Mn4+ and Ti4+/Ti3+, respectively. When constructed to a symmetric full battery, it exhibits a moderate reversible capacity of 91.8 mAh/g with a high initial Columbic efficiency of 85.2%, and maintains 70.8% of discharge capacity after 400 cycles at 1C. This work deepens our understanding of materials design for enhanced pseudocapacitance and electrochemical performances.

Ke Cheng

Postdoctoral Researcher

My research interests lie at the surface of chemistry and biology, where I am deeply passionate about applying innovative chemistry to advance fields such as chemoproteomics, drug discovery, nanomedicine, and theranostics. My aim is to provide robust methodologies for mapping biological interactomes, accelerating drug development, and expanding therapeutic opportunities.